Adaptive Biotechnologies Corporation (ADPT)
Healthcare · NMS
Price as at 30 Sept 2026, 16:05 UTC. Quotes are delayed.
Fundamentals
Valuation and ratings
Adaptive Biotechnologies Corporation trades at $29.32. Our model's figure for Adaptive Biotechnologies Corporation is more than three times the share price, or less than a third of it. A gap that size is far more often a data problem than a real mispricing, so we publish no estimate until the inputs produce one that passes this check.
Our moat model scores it 40 out of 100, which is little in the way of a moat. A moat is a structural reason competitors cannot take the profits away, and it matters more to a long holding period than any single quarter's numbers do.
ADPT earnings and analyst estimates
Recommendation mix, 8 published ratings
Estimates are the published analyst consensus and move often. An earnings date is scheduled, not certain, and a share tends to reprice most violently on the day itself.
About Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Company profile, industry and headcount are as reported by our data provider and can lag a company's own filings by a reporting period. The annual report is the authority.
ADPT passes 2 of our 30 screens today
Each screen prints the exact criteria it used, and the circumstances in which it is wrong.
Super investor ownership
13 of the funds we track reported a position in their latest SEC 13F filing. Largest first:
- Andreas Halvorsen, VIKING GLOBAL INVESTORS LP$643.37M · 1.8% of book
- D. E. Shaw, D. E. Shaw & Co., Inc.$99.22M · 0.1% of book
- Arrowstreet Capital, ARROWSTREET CAPITAL, LIMITED PARTNERSHIP$54.15M · 0.0% of book
- Cathie Wood, ARK Investment Management LLC$44.84M · 0.3% of book
- Paul Tudor Jones, TUDOR INVESTMENT CORP ET AL$11.66M · 0.0% of book
A word of warning on reading these figures: a 13F reports the market value of a holding, so a fund that traded nothing at all still appears to have sold when the price fell. We found 102 companies where the standard reading gives the opposite answer. Only the share count is honest.
ADPT peers
The largest companies in the same industry (Diagnostics & Research), then in the same sector.
- TMO Thermo Fisher Scientific Inc.
- WAT Waters Corporation
- DGX Quest Diagnostics Incorporated
- ICLR ICON Public Limited Company
- CRL Charles River Laboratories International, Inc.
- QIA.DE Qiagen N.V.
- BLLN BillionToOne, Inc.
- SHC Sotera Health Company
Every healthcare company we cover is on the Healthcare hub.
Common questions
Which funds own ADPT?
13 of the institutions we track reported a position in ADPT in their most recent SEC 13F filing. A 13F is filed up to 45 days after quarter end, so it tells you what a fund held then, not what it holds now.
Where does SteadyShares get its ADPT data?
Fundamentals for ADPT come from company filings and exchange data, as listed on NMS; institutional ownership comes from SEC 13F filings. The share price shown was last refreshed on 30 Sept 2026, 16:05 UTC and is delayed. Our data quality score for this company is 83/100, which is the share of the inputs behind our scores that were actually available rather than assumed. Metrics we do not hold are left out of the page rather than estimated.
The full research page for ADPT, with financial statements, ownership detail, peer comparison and alerts, is free inside the app.
Data from company filings, exchange quotes and SEC EDGAR 13F disclosures. Quotes are delayed. Metrics we do not have are left out rather than estimated. Educational information, not financial advice.